Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy

Leukemia

Volumn 20, Issue 1, 2006, Pages 35-41

  de Botton, S ^a,c   Sanz, M A ^b,c   Chevret, S ^a   Dombret, H ^a   Martin, G ^b   Thomas, X ^a   Mediavilla, J D ^b   Recher, C ^a   Ades, L ^a   Quesnel, B ^a   Brault, P ^a   Fey, M ^a   Wandt, H ^a   Machover, D ^a   Guerci, A ^a   Maloisel, F ^a   Stoppa, A M ^a   Rayon, C ^b   Ribera, J M ^b   Chomienne, C ^a   Degos, L ^a   Fenaux, P ^a   more..

^a The European APL Group   (France)

^b PETHEMA Group   (Spain)

^c AVICENNE HOSPITAL   (France)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Extramedullary relapse

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA;

ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FREQUENCY ANALYSIS; HUMAN; HUMAN CELL; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SKIN CANCER; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

EID: 33644976445     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404006     Document Type: Article

References (31)

1. Fenaux P, Chevret S, Guerci A, Fegueux N, Dombret H, Thomas X et al. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group. Leukemia 2000; 14: 1371-1377.
2. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG et al. All-trans retinoic acid in acute promyelocytic leukemia: Long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002; 100: 4298-4302.
3. Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C et al. Molecular remission inPML/RAR-positive acute promyelocytic leukemia by combined all-trans retinoic acid, idarubicin (AIDA) therapy. Blood 1997; 90: 1014-1021.
4. Sanz MA, Martin G, Rayon C, Esteve J, Gonzalez M, Diaz-Mediavilla J et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 1999; 94: 3015-3021.
5. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999; 94: 1192-2000.
6. Sanz MA, Martin G, Gonzalez M, Leon A, Rayon C, Rivas C et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: A multicenter study by the PETHEMA Group. Blood 2004; 103: 1237-1243.
7. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: Evolving therapeutic strategies. Blood 2002; 99: 759-767.
8. Ohno R, Asou N, Ohnishi K. Treatment of acute promyelocytic leukemia: Strategy toward further increase of cure rate. Leukemia 2003; 17: 1454-1463.
9. Wiernik PH, De Bellis R, Muxi P, Dutcher JP. Extramedullary acute promyelocytic leukemia. Cancer 1996; 78: 2510-2514.
10. Byrd JC, Edenfield WJ, Shields DJ, Dawson NA. Extramedullary myeloid cell tumors in acute non lymphocytic leukemia: A clinical review. J Clin Oncol 1995; 13: 1800-1816.
11. Marra R, Storti S, Pagano L. Central nervous system acute promyelocytic leukemia: A report of three cases. Haematologica 1989; 3: 195-199.
12. Evans GD, Grimwade DJ. Extramedullary disease in acute promyelocytic leukemia. Leuk Lymphoma 1999; 33: 219-229.
13. Liso V, Specchia G, Pogliani EM, Palumbo G, Mininni D, Rossi V et al. Extramedullary involvement in patients with acute promyelocytic leukemia: A report of seven cases. Cancer 1998; 83: 1522-1528.
14. Ko B-S, Tang G-L, Chen Y-C, Yao M, Wang CH, Shen MC et al. Extramedullary relapse after all-trans retinoic acid treatment in acute promyelocytic leukemia. The occurrence of retinoic acid syndrome is a risk factor. Leukemia 1999; 13: 1406-1408.
15. Sanz MA, Larrea L, Sanz G, Martin G, Sempere A, Gomis F et al. Cutaneous promyelocytic sarcoma at sites of vascular access, marrow aspiration. A characteristic localization of chloromas in acute promyelocytic leukemia? Haematologica 2000; 85: 758-762.
16. Specchia G, Lo Coco F, Vignetti M, Avvisati G, Albano V, Fazi P et al. Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with ATRA. A report by the Gimema group. J Clin Oncol 2001; 19: 4023-4028.
17. Breccia M, Carmosino I, Diverio D, De Santis S, De Propris MS, Romano A et al. Early detection of meningeal localization in acute promyelocytic leukaemia patients with high presenting leucocyte count. Br J Haematol 2003; 120: 266-270.
18. Breccia M, Petti MC, Testi AM, Specchia G, Ferrara F, Diverio D et al. Ear involvement in acute promyelocytic leukemia at relapse: A disease-associated 'sanctuary'? Leukemia 2002; 16: 1127-1130.
19. Eclache V, Benzacken B, Le Roux G, Casassus P, Chomienne C. PML/RAR alpha rearrangement in acute promyelocytic leukaemia with t(1;17) elucidated using fluorescence in situ hybridization. Br J Haematol 1997; 98: 440-443.
20. Bolufer P, Barragán E, Sanz MA, Martín G, Bornstein R, Colomer D et al. Preliminary experience in external quality control of RT-PCR PML/RARα detection in promyelocytic leukemia. Leukemia 1998; 12: 2024-2028.
21. Prentice RL, Kalbfleish JD, Peterson AV, Flournoy N, farewell N, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics 1978; 34: 541-554.
22. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist 1988; 16: 1115-1141.
23. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. JASA 1999; 94: 496-509.
24. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J Roy Stat Soc 1972; 135: 185-206.
25. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-472.
26. Guglielmi C, Martelli MP, Diviero D, Fenu S, Vegna ML, Cantu-Rajnoldi A et al. Immunophenotype of adult and childhood acute promyelocytic leukaemia: Correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. Br J Haematol 1998; 102: 1035-1041.
27. Gonzalez M, Barragan E, Bolufer P, Chillon C, Colomer D, Borstein R et al. Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RAR alpha isoforms: A study of the PETHEMA group. Br J Haematol 2001; 114: 99-103.
28. Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayon C, Barbui T et al. Definition of relapse risk and role of ninanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA Cooperative Groups. Blood 2000; 96: 1247-1253.
29. de Bolton S, Coiteux V, Chevret S, Rayon C, Vilmer E, Sanz M et al. Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. J Clin Oncol 2004; 22: 1404-1412.
30. Ferrara F, Morabito F, Martino B, Specchia G, Liso V, Nobile F et al. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J Clin Oncol 2000; 18: 1295-1300.
31. Ravandi F, Cortes J, Estrov Z, Thomas D, Giles FJ, Huh YO et al. CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia. Leuk Res 2002; 26: 643-649.